Cover ImageSALE
Market Research Report

Global Nanoparticles Market in Biotechnology and Pharmaceutical Sectors 2017-2021

Published by TechNavio (Infiniti Research Ltd.) Product code 582989
Published Content info 88 Pages
Delivery time: 1-2 business days
Price
Back to Top
Global Nanoparticles Market in Biotechnology and Pharmaceutical Sectors 2017-2021
Published: November 20, 2017 Content info: 88 Pages
Description

About Nanoparticles

Nanoparticles are sub-nanosized colloidal structures composed of synthetic or semi-synthetic polymers. These are used in biotechnology and pharmaceutical sectors for studying biological systems for diagnosing diseases and focusing on treatment at the molecular level. The properties of many conventional materials alter when formed from nanoparticles, the reason being nanoparticles have a greater surface area per weight than larger particles, making them more reactive to other molecules

Technavio's analysts forecast the global nanoparticles market in biotechnology and pharmaceutical sectors to grow at a CAGR of 21.72% during the period 2017-2021.

Covered in this report

The report covers the present scenario and the growth prospects of the global nanoparticles market in biotechnology and pharmaceutical sectors for 2017-2021. To calculate the market size, the report considers the revenue generated from the retail sales of nanoparticles in the aforesaid sectors.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

Technavio's report, Global Nanoparticles Market in Biotechnology and Pharmaceutical Sectors 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • F. Hoffmann-La Roche
  • GE Healthcare
  • Merck
  • Novartis

Other Prominent Vendors

  • AMAG Pharmaceuticals
  • Amgen
  • Bausch & Lomb
  • Biogen
  • Celgene
  • Gilead
  • Ipsen
  • Leadiant Biosciences
  • nanoComposix
  • Pacira Pharmaceuticals
  • Pfizer
  • Shire
  • UCB

Market driver

  • Rising R&D expenditure in pharmaceutical and biotechnology sectors
  • For a full, detailed list, view our report

Market challenge

  • Challenges in development of nanoparticles for therapeutics
  • For a full, detailed list, view our report

Market trend

  • Increasing demand for nanoparticles in stem cell therapy
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2021 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents
Product Code: IRTNTR15521

Table of Contents

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: INTRODUCTION

  • Market outline

PART 05: MARKET LANDSCAPE

  • Market size and forecast
  • Five forces analysis

PART 06: MARKET SEGMENTATION BY END-USER

  • Comparison by end-user
  • Biotechnology
  • Pharmaceutical
  • Market opportunity by end-user

PART 07: REGIONAL LANDSCAPE

  • Regional comparison
  • Nanoparticles market in biotechnology and pharmaceutical sectors in Americas
  • Nanoparticles market in biotechnology and pharmaceutical sectors in EMEA
  • Nanoparticles market in biotechnology and pharmaceutical sectors in APAC
  • Market opportunity

PART 08: DECISION FRAMEWORK

PART 09: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 10: MARKET TRENDS

  • Increasing demand for nanoparticles in stem cell therapy
  • Increasing prevalence of chronic diseases
  • Increasing use of gold nanoparticles

PART 11: VENDOR LANDSCAPE

  • Competitive scenario
  • Investment opportunity

PART 12: VENDOR ANALYSIS

  • Vendor overview
  • Merck
  • F. Hoffmann-La Roche
  • GE Healthcare
  • Novartis
  • Other prominent vendors

PART 13: APPENDIX

  • List of abbreviations

List of Exhibits

  • Exhibit 01: Applications of nanoparticles in biotechnology and pharmaceutical sectors
  • Exhibit 02: Detection of cancer cells in bloodstream through use of nanoparticles
  • Exhibit 03: Global nanoparticles market in biotechnology and pharmaceutical sectors: Market overview
  • Exhibit 04: Global nanoparticles market in biotechnology and pharmaceutical sectors 2016-2021 ($ billions)
  • Exhibit 05: Five forces analysis
  • Exhibit 06: Global nanoparticles market in biotechnology and pharmaceutical sectors by end-user 2016-2021 (% share)
  • Exhibit 07: Comparison by end-user
  • Exhibit 08: Global nanoparticles market by biotechnology 2016-2021 ($ billions)
  • Exhibit 09: Global nanoparticles market by biotechnology - Year over year growth
  • Exhibit 10: Global nanoparticles market by pharmaceutical 2016-2021 ($ billions)
  • Exhibit 11: Nanoparticles in pharmaceuticals
  • Exhibit 12: Global nanoparticles market by pharmaceutical - Year over year growth
  • Exhibit 13: Global nanoparticles market in biotechnology and pharmaceutical sectors by region 2016-2021 (% share)
  • Exhibit 14: Regional comparison
  • Exhibit 15: Nanoparticles market in biotechnology and pharmaceutical sectors in Americas 2016-2021 ($ billions)
  • Exhibit 16: Nanoparticles market in biotechnology and pharmaceutical sectors in Americas - Year over year growth
  • Exhibit 17: Top 3 countries in Americas
  • Exhibit 18: Nanoparticles market in biotechnology and pharmaceutical sectors in EMEA 2016-2021 ($ billions)
  • Exhibit 19: Nanoparticles market in biotechnology and pharmaceutical sectors in EMEA - Year over year growth
  • Exhibit 20: Top 3 countries in EMEA
  • Exhibit 21: Nanoparticles market in biotechnology and pharmaceutical sectors in APAC 2016-2021 ($ billions)
  • Exhibit 22: Nanoparticles market in biotechnology and pharmaceutical sectors in APAC - Year over year growth
  • Exhibit 23: Top 3 countries in APAC
  • Exhibit 24: Nanoparticle-based products under clinical trials
  • Exhibit 25: Major chronic disease-related deaths 2012 (in thousands)
  • Exhibit 26: Strategic success factors for vendors to consider
  • Exhibit 27: Investment opportunity mapping
  • Exhibit 28: Merck: Profile
  • Exhibit 29: Merck: Strength analysis
  • Exhibit 30: Merck: Strategy assessment
  • Exhibit 31: Merck: Opportunity assessment
  • Exhibit 32: F. Hoffmann-La Roche: Profile
  • Exhibit 33: F. Hoffmann-La Roche: Strength analysis
  • Exhibit 34: F. Hoffmann-La Roche: Strategy assessment
  • Exhibit 35: F. Hoffmann-La Roche: Opportunity assessment
  • Exhibit 36: GE Healthcare: Profile
  • Exhibit 37: GE Healthcare: Strength analysis
  • Exhibit 38: GE Healthcare: Strategy assessment
  • Exhibit 39: GE Healthcare: Opportunity assessment
  • Exhibit 40: Novartis: Profile
  • Exhibit 41: Novartis: Strength analysis
  • Exhibit 42: Novartis: Strategy assessment
  • Exhibit 43: Novartis: Opportunity assessment
Back to Top